Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Cue Biopharma, Inc. announced that the FDA has granted Fast Track designation to CUE-101, its lead clinical drug candidate from the CUE-100 series of interleukin 2-based biologics, for the treatment of patients with human papilloma virus recurrent/metastatic head and neck squamous cell carcinoma as a monotherapy and in combination with pembrolizumab.